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http://www.biomedcentral.com/1471-2407/14/977RESEARCH ARTICLE Open AccessIdentification of a candidate prognostic gene
signature by transcriptome analysis of matched
pre- and post-treatment prostatic biopsies from
patients with advanced prostate cancer
Prabhakar Rajan1*†, Jacqueline Stockley1†, Ian M Sudbery2†, Janis T Fleming3, Ann Hedley3, Gabriela Kalna3,
David Sims2, Chris P Ponting2, Andreas Heger2, Craig N Robson4, Rhona M McMenemin5, Ian D Pedley5
and Hing Y Leung6*Abstract
Background: Although chemotherapy for prostate cancer (PCa) can improve patient survival, some tumours are
chemo-resistant. Tumour molecular profiles may help identify the mechanisms of drug action and identify potential
prognostic biomarkers. We performed in vivo transcriptome profiling of pre- and post-treatment prostatic biopsies
from patients with advanced hormone-naive prostate cancer treated with docetaxel chemotherapy and androgen
deprivation therapy (ADT) with an aim to identify the mechanisms of drug action and identify prognostic biomarkers.
Methods: RNA sequencing (RNA-Seq) was performed on biopsies from four patients before and ~22 weeks after
docetaxel and ADT initiation. Gene fusion products and differentially-regulated genes between treatment pairs were
identified using TopHat and pathway enrichment analyses undertaken. Publically available datasets were interrogated
to perform survival analyses on the gene signatures identified using cBioportal.
Results: A number of genomic rearrangements were identified including the TMPRSS2/ERG fusion and 3 novel gene
fusions involving the ETS family of transcription factors in patients, both pre and post chemotherapy. In total, gene
expression analyses showed differential expression of at least 2 fold in 575 genes in post-chemotherapy biopsies. Of
these, pathway analyses identified a panel of 7 genes (ADAM7, FAM72B, BUB1B, CCNB1, CCNB2, TTK, CDK1), including
a cell cycle-related geneset, that were differentially-regulated following treatment with docetaxel and ADT. Using
cBioportal to interrogate the MSKCC-Prostate Oncogenome Project dataset we observed a statistically-significant
reduction in disease-free survival of patients with tumours exhibiting alterations in gene expression of the above
panel of 7 genes (p = 0.015).
Conclusions: Here we report on the first “real-time” in vivo RNA-Seq-based transcriptome analysis of clinical PCa from
pre- and post-treatment TRUSS-guided biopsies of patients treated with docetaxel chemotherapy plus ADT. We identify
a chemotherapy-driven PCa transcriptome profile which includes the down-regulation of important positive regulators
of cell cycle progression. A 7 gene signature biomarker panel has also been identified in high-risk prostate cancer
patients to be of prognostic value. Future prospective study is warranted to evaluate the clinical value of this panel.
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The mainstay of treatment for “incurable” locally-advanced/
metastatic prostate cancer (PCa) is androgen deprivation
therapy (ADT) [1], however after ~2-3 years the dis-
ease becomes castration-resistant (CRPCa). Historically,
patients with CRPCa exhibited a median survival of less
than ~18 months, although this has improved since the
advent of novel chemo- and endocrine therapies [2]. The
anti-mitotic agent docetaxel was the first chemotherapeutic
agent to demonstrate a significant survival advantage
for patients with CRPCa [3,4]. Docetaxel stabilizes micro-
tubules, thereby interrupting microtubule dynamics
(including the mitotic spindle) causing mitotic arrest and
accumulation of cells in G2/M (due to failure chromosome
segregation and cytokinesis) and apoptosis [5,6].
Early trials demonstrated an overall median ~2-3
month survival advantage for docetaxel-based therapies
over standard treatments for CRPCa [3,4], supporting its
recommendation as first-line standard of care for CRPCa
[1]. However, only ~50% of patients with CRPCa will re-
spond to docetaxel, and the modest survival advantage is at
the cost of significant toxicity [3,4]. Recently, docetaxel plus
ADT have been found to confer no statistically-significant
survival advantage over ADT alone for non-CRPCa
(i.e. hormone-naïve disease), despite an improvement in
clinical and biochemical progression-free survival [7].
An understanding of the biology of de novo and acquired
chemo-resistance to docetaxel (and other agents) in PCa
with in-parallel biomarker discovery will help to identify
patients who will not benefit from treatment prior to expos-
ure, thereby avoiding unnecessary toxicity and guiding more
effective therapeutic options. Aided by technological ad-
vances such as next generation sequencing which facilitate
whole genome and transcriptome analyses, molecular profil-
ing of pre- and post-treatment tumour samples may help to
identify the mechanisms of drug action and link specific
gene amplifications and mutations or expression changes to
clinical chemo-sensitivity or -resistance patterns [8].
Previously-published transcriptome-wide analyses of
docetaxel action and chemo-resistance in PCa have utilised
microarrays for assessment of pre- and post-extirpative
surgical specimens [9,10] and in vitro cell lines [3,11-13].
However, these studies are limited by the inherent bias and
quantitative nature of microarray data [14]. We performed
in vivo transcriptome profiling by next generation RNA se-
quencing (RNA-Seq) of pre- and post-treatment transrectal
ultrasound (TRUSS)-guided prostatic biopsies from patients
with newly-diagnosed locally-advanced/metastatic non-
CRPCa treated with docetaxel chemotherapy plus ADT.
Methods
Patient samples
Patient samples for gene expression analysis (RNA-Seq)
were collected as part of the GenTax (Tumour profilingin an open-labelled, two-arm study investigating the
tolerability and efficacy of Taxotere in patients with
hormone-naïve high-risk prostate cancer) study by
Newcastle upon Tyne Hospitals National Health Service
(NHS) Foundation Trust [15]. All patients with a clin-
ical suspicion of advanced PCa were subjected to
TRUSS-guided prostatic biopsy (BK Medical, 8818)
for histopathological assessment by Gleason Sum score
[16] of Haematoxylin and Eosin (H&E)-stained tissue.
Radiological staging investigations were performed
according to national guidelines [17]. Patient eligibility
criteria were cT3/T4 [18] PCa, Prostate Specific Antigen
(PSA) ≥50 ng/ml or Gleason Sum score ≥8, or metastatic
disease to be commenced on ADT. Further eligibility for
study inclusion were Karnofsky Performance status (KPS)
Score [19] ≥ 70%; a life expectancy of ≥ 3 months; and
adequate haematological, hepatic, and renal function. All
patients received ADT, which consisted of the goserelin
3.6 mg on a q28-day schedule with anti-androgen “flare”
protection and 6 cycles of docetaxel (Taxotere®) 75 mg/m2
on a q21-day schedule [15]. Further material for RNA-Seq
was taken by TRUSS-guided biopsy prior to commence-
ment of chemotherapy and again at ~22 weeks following
initiation of treatment. Biopsies were specifically taken
from tumour-rich areas of the prostate, where typically
over 60% of the initial diagnostic cores taken were occupied
by tumour. All patient material was anonymized and
stored at −80°C. Serum PSA was measured ~3-weekly
until ~22 weeks and then 3-monthly, and repeat
radiological staging undertaken at ~6 months after
diagnosis for patients with N+ and/or M+ disease to
assess the radiological response. PSA progression was
defined as two consecutive rises in PSA above nadir
at least 2 weeks apart, although whether patients subse-
quently fulfilled the European Association of Urology
(EAU) criteria for castration resistant PCa disease [1] is not
known. Written informed consent to participate was
obtained from all subjects. Ethical approval was
granted from the local research and ethics committee
(Northumberland, Tyne and Wear NHS Strategic Health
Authority Local Research Ethics Committee Ref: 2003/11).
RNA extraction and RNA-Seq
Patient samples for RNA-Seq were analysed as previously
described [20]. Total RNA was extracted from pre- and
post-treatment samples using the RNeasy Mini Kit
(QIAgen, 74104) according to manufacturer’s instructions.
The NanoDrop 2000 spectrophotometer (Thermo
Scientific) and 2100 Bioanalyzer (Agilent) were used
to assess RNA quantity and quality, with calculation
of RNA integrity number (RIN) [21]. Samples were
included for RNA-Seq if RIN> 6 and total RNA> 500 ng.
Illumina RNA-Seq was performed according to manufac-
turer’s instructions, with cDNA sample library normalization
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prior to cluster generation and library sequencing on
the HiSeq™ 2000 (Illumina) with a paired-end sequencing
strategy. The read length was set at 90 nt with an expected
library size of 200 bp.
Bioinformatics
The FastQC package (http://www.bioinformatics.babraham.
ac.uk/projects/fastqc) was used to assess the quality of
raw reads, which were then mapped to human genome
assembly hg19 using TopHat version 1.4.1 [22] with a
junctions library derived from Ensembl version 68.
Quality control was performed on all samples by
examining the following parameters: (a) the percent
of reads uniquely mapping to the genome; (b) the
percent of reads mapping to known protein coding
sequence; (c) the number of exon junctions identified;
(d) the percent of spliced reads; and (e) the number of
genes with 90% base coverage (Additional file 1: Table S1).
TopHat-Fusion version 0.1.0 [23] was used to identify gene
fusions. HTSeq version 0.5.3 (http://www.huber.embl.de/
users/anders/HTSeq) was used to identify differentially-
expressed genes by counting the number of reads mapping
to each gene from Ensembl version 68. The TMM method
was used to normalise read counts and differential
expression tested for using a paired generalized linear
model design with the Bioconductor version 2.11
edgeR package [24]. The Circos plot was generated
using RCircos version 1.1.2 [25]. Correlations were identi-
fied using Pearson’s product moment correlation coefficient
(p < 0.05). Enriched KEGG (Kyoto Encyclopedia of
Genes and Genomes) pathways [26] were identified
by downloading gene pathways associations and testing
each pathway for enrichment in significantly up- and
down-regulated genes (FDR < 0.05) with a transcript
length-corrected Wallenius approximation as imple-
mented by the GOSeq package for Bioconductor 3.0 [27].
Pathways were deemed to be enriched if the enrich-
ment over background was at least 2-fold and the
FDR < 0.05. Gene lists were uploaded to cBioPortal
(http://www.cbioportal.org) [28,29] to study gene expressionTable 1 Patient demographics of samples for RNA-Seq follow
Patient KPS GSS T N M
1 90 9 4 1 1
2* 90 7$ 3b 1 0
3* 90 8 3b 0 0
4 90 7 3b 1 1
5 90 9 3b 0 0
6 90 7 3b 1 1
All patients exhibited a response to docetaxel plus ADT prior to second TRUSS-guid
second TRUSS-guided biopsy was 156 ± 37 days. *Samples removed from RNA-seq a
GSS = Gleason Sum Score; iPSA = initial PSA value at diagnosis; nPSA = nadir PSA va
survival; N/P = not yet progressed).changes in all prostate tumours with mRNA expression
data (n = 150) from the Memorial Sloan Kettering Cancer
Center (MSKCC) Prostate Oncogenome Project dataset
[30] using a mRNA Z-score threshold of ± 1.6 as compared
with normal prostate samples. Genes altered in a sig-
nificant number of tumours (>25%) were considered
for associations with disease-free survival though the
cBioPortal software using the Kaplan–Meier method
with log rank testing with p < 0.05 taken to indicated statis-
tical significance. Raw sequencing data have been deposited
at Gene Expression Omnibus (http://www.ncbi.nlm.nih.
gov/geo/) under accession number GSE51005 and all
details are MIAME compliant.
Results
The transcriptomic landscape of docetaxel chemotherapy
plus ADT in PCa
Next generation RNA sequencing (RNA-Seq) was
performed on 12 paired pre- and post-docetaxel plus
ADT samples from 6 patients with locally-advanced/
metastatic PCa (Table 1). The post-treatment samples
from Patients 2 and 3 performed markedly worse on
multiple quality control measures, and so all samples
from both patients were excluded from further quantita-
tive expression analysis (Additional file 1: Table S1). The
remaining 8 samples matched our previously-published
dataset on the ADT-only control arm of the GenTax
study [20] on two key quality control measures: At
least 50 million 90 bp paired-end reads were obtained
per sample with at least 40% coverage of transcripts
sequenced (Additional file 1: Table S1).
Genomic rearrangements involving ETS-family tran-
scription factors are implicated in PCa with the most
common gene fusion product TMPRSS2/ERG reported
in >50% cases [31]. We searched for expression of tran-
scripts derived from such gene fusions in our datasets. We
observed the intra-chromosomal TMPRSS2/ERG gene
fusion product in only the pre-treatment sample from 1
patient (Patient 3), which was actually excluded from the
quantitative expression analysis (Additional file 2: Table S2).
However, we observed 3 further novel intra-chromosomaling docetaxel chemotherapy plus ADT
iPSA (ng/ml) nPSA (ng/ml) (% iPSA) PFS (days)
8.76 0.09 (1.0) 317
8.44 1.3 (15.4) 105
25.8 0.19 (0.7) 834
80.8 0.08 (0.1) 588
2.85 0.08 (2.8) N/P
636 0.1 (0.0) N/P
ed biopsy as determined by a fall in levels of serum PSA. The mean time to
nalysis. $Tertiary Gleason grade 5. (KPS = Karnofsky Performance Status;
lue prior to second TRUSS-guided biopsy; PFS = biochemical progression-free
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between DOPEY2 and ERG genes within chromosome 21
(Fusion event 7), and 2 different gene fusions were observed
within chromosome 22 (Fusion events 3 and 4) (Figure 1A).
A further five novel fusion transcripts were identified
(Figure 1A and Additional file 2: Table S2). In three
patients, identical inter- and intra-chromosomal gene
fusions (CCNY/LRCC49, PVT1/CPNE4, and DOPEY2/ERG)
were identified in both pre- and post-treatment samples.Figure 1 Differential expression of androgen-regulated genes in resp
the transcriptomic landscape of docetaxel chemotherapy plus ADT in PCa.
chromosome identities. The scatter plot shows up- (Red) and down- (Blue)
genomic loci. (B) Log-log plot demonstrating correlation between KLK3 (en
means of M-value (TMM) in normalized counts per million (ncpm) and seru
known androgen-regulated genes (Log2 fold change≥ 2; FDR < 0.05) followAcross the genome, we observed a total of 298 genes
up-regulated and 277 genes similarly down-regulated
at least 2-fold (False Discovery Rate [FDR] <0.05) in
response to docetaxel plus ADT (Figure 1A, Table 2
and Additional file 3: Table S3). The levels of expres-
sion of KLK3, which encodes PSA (Prostate Specific
Antigen), detected by RNA-Seq of the docetaxel plus
ADT arm correlated as expected with serum PSA
levels (r2 = 0.927; p = 0.037) (Figure 1B). A number ofonse to docetaxel chemotherapy plus ADT. (A) Circos plot [25] of
The outer ring shows chromosome ideograms with labelled
regulated genes. Gene fusions are shown as coloured arcs linking two
codes PSA) mRNA expression levels (X-axis) normalized by trimmed
m PSA levels (ng/ml) (Y-axis) (r2 = 0.927; p = 0.037). (C) Expression of
ing docetaxel plus ADT.
Table 2 Differentially-expressed genes following
docetaxel chemotherapy plus ADT versus ADT alone
Gene set Tax ADT
Up Down Up Down
Protein Coding 298 277 774 755
Non-Coding 7 15 35 116
Numbers of protein coding and non-coding genes differentially expressed at
least 2-fold after ADT with FDR < 0.05. (ADT = androgen deprivation
therapy; Tax = docetaxel + ADT).
Rajan et al. BMC Cancer 2014, 14:977 Page 5 of 10
http://www.biomedcentral.com/1471-2407/14/977other known androgen-regulated genes (including those
encoding kallikreins) were also consistently down-
regulated in the docetaxel plus ADT arm (Figure 1C)
suggesting that ADT in combination with docetaxel
had the expected action on androgen-regulated gene
expression.
Based on the full gene list (Log2 fold change ≥2/≤ − 2;
FDR < 0.05) (Table 2 and Additional file 3: Table S3),
we ranked genes according to the magnitude of their
fold changes, regardless of whether they were up- or
down-regulated. The 10 top-ranking genes differentially-
regulated by docetaxel plus ADT were arbitrarily selected
(range of fold changes −9.96 to 9.86) for further down-
stream knowledge-based validation. From these 10 genes,
we selected genes that exhibited expression changes
consistent in direction in at least 3 out of 4 patients. We
identified 6 differentially-expressed genes (Figure 2A)
including ORM1, which had the highest average level
of differential expression of all transcripts in our dataset
(Log2 fold change = −9.96; FDR < 0.05). This gene encodes
an acute phase plasma protein that has been identified as
a putative biomarker of chemo-resistance to docetaxel
and doxorubicin in breast cancer [13].
Using cBioPortal [28,29], we interrogated the MSKCC
Prostate Oncogenome Project dataset (n = 150) [30] for
changes in expression of the above 6 genes in treatment-
naive prostate tumours as compared with normal controls.
We observed alterations in expression of all 6 genes, with
FAM72B and ADAM7 exhibiting significant alterations
(Figure 2B). Survival analysis identified a statistically-
significant reduction in disease-free survival of patients
with tumours exhibiting alterations in expression of this
geneset (p = 0.023) (Additional file 4: Figure S1A)
which was lost when FAM72B and ADAM7 were removed
from the geneset (p > 0.05) (data not shown). Using
only FAM72B and ADAM7, survival analysis demon-
strated a statistically-significant disease-free survival
advantage in patients with no alterations in gene expres-
sion (p = 0.001) (Figure 2C). Taken together, these data
suggest that alterations in expression of FAM72B and
ADAM7 are associated with early treatment relapse
and hence may be biomarkers with prognostic value in
treatment-naïve PCa.Pathway analyses of gene expression changes in
response to docetaxel chemotherapy and ADT
To identify biological pathways perturbed by combined
docetaxel chemotherapy with ADT, we performed an
enrichment analysis on our lists of up- and down-regulated
genes (FDR < 0.05) using 3 different pathways analysis tools:
the KEGG (Kyoto Encyclopedia of Genes and Genomes)
database [26]; IPA “Core Analysis” function; and
Metacore (Figure 3 and Additional file 5: Figure S2,
Additional file 6: Table S4 and Additional file 7: Table S5).
The KEGG terms “Cell Cycle” (n = 11/124; enrichment =
5.89-fold; FDR = 0.0014) and “Steroid Biosynthesis”
(n = 5/19; enrichment = 17.63-fold; FDR = 0.0014) were
enriched greater than 2-fold in the down-regulated
gene list (Additional file 6: Table S4), while no pathways
were significantly enriched in the up-regulated gene list.
Genes within the KEGG term “Cell Cycle” included the
key positive cell cycle regulators CCNB1, CCNB2, CDK1
and CDC25A (Figure 3A and Additional file 8: Table S6),
the expression of which was down-regulated following
docetaxel plus ADT. The Ingenuity Pathway Analysis “Core
Analysis” function also identified the “Cell Cycle” as the
highest-ranking network containing clusters of docetaxel
and ADT-regulated genes (Additional file 5: Figure S2A
and Additional file 7: Table S5). Metacore analysis of
docetaxel and ADT-regulated genes identified Cell
cycle “The metaphase checkpoint” as the 2nd top enriched
pathway after Cytoskeleton remodelling “Keratin filaments”,
which is consistent with the known actions of docetaxel
(Additional file 5: Figure S2B).
The observed enrichment for cell cycle-related genes,
including down-regulation of expression of positive
regulators of cell cycle progression, is in keeping with
the known actions of docetaxel in vitro on the induction
of G2/M arrest [5]. In the light of evidence suggesting that
androgen withdrawal may diminish docetaxel-induced
apoptosis in vitro [32], we wished to ensure that our
in vivo observations were consistent with the mechan-
ism of action of docetaxel in vitro in the absence of
androgens. We used the LNCaP PCa cell line grown in
steroid-depleted medium as a model for non-CRPCa treated
with ADT. Reassuringly, we observed statistically-significant
induction of G2/M arrest (p < 0.05) following treat-
ment with docetaxel (at 10 nM, 100 nM or 1 μM doses)
(Additional file 5: Figure S2C).
Finally, we used cBioPortal [28,29] to interrogate the
MSKCC Prostate Oncogenome Project dataset [30] for
changes in expression of the genes enriched within
the KEGG term “Cell Cycle” in clinical PCa and observed
alterations in expression of all genes in a large (78%)
proportion of cases (Additional file 5: Figure S2D),
suggesting that expression of these transcripts is associated
with prostate tumourigenesis. Survival analyses did not
identify any statistically-significant associations between
Figure 2 Differential expression of genes affected by docetaxel chemotherapy plus ADT. (A) Log2 fold change of 6 of the 10 top-ranking
differentially-expressed genes (Log2 fold change≥ 2/≤ − 2; FDR < 0.05) consistent in the direction of expression changes in at least 3 out of 4
individual patients. (B) Matrix heatmap generated using cBioPortal [28,29] showing alterations in expression of 6 of the top 10 differentially-regulated
genes (exhibiting consistent expression changes in at least 3 out of 4 patients in the present study) in the MSKCC Prostate Oncogenome Project
dataset [30]. (C) Kaplan Meier plot showing the survival curves of patients in the MSKCC Prostate Oncogenome Project dataset with and without
alterations in expression of FAM72B and ADAM7 (p = 0.001).
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ing alterations in expression of these genes as compared
with patients with tumours exhibiting no alterations in
expression (p > 0.05) (data not shown). However, when
genes exhibiting alterations in high (>25%) proportion oftumours only were included in this geneset (Figure 3B), we
observed statistically-significant reduction in disease-free
survival of patients with tumours exhibiting alterations in
expression of this geneset (p = 0.024) (Figure 3C). Using a
combined geneset of these 5 remaining cell cycle-related
Figure 3 Pathway analyses of gene expression changes in response to docetaxel chemotherapy with ADT. (A) Log2 fold change of genes
enriched (enrichment > 2-fold; FDR < 0.05) within the KEGG (Kyoto Encyclopedia of Genes and Genomes) [26] term “Cell Cycle” following
docetaxel plus ADT treatment. (B) Matrix heatmap generated using cBioPortal [28,29] showing alterations in expression of 5 genes from within
the KEGG term “Cell Cycle” (BUB1B, CCNB1, CCNB2, TTK, and CDK1) in the MSKCC Prostate Oncogenome Project dataset [30]. (C) Kaplan Meier plot
showing the survival curves of patients in the MSKCC Prostate Oncogenome Project dataset with and without alterations in expression of the 5
cell cycle-related genes (p = 0.024). (D) Kaplan Meier plot showing the survival curves of patients in the MSKCC Prostate Oncogenome Project
dataset with and without alterations in expression of the genes in the candidate biomarker panel (ADAM7, FAM72B, BUB1B, CCNB1, CCNB2, TTK
and CDK1) (p = 0.015).
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as ADAM7 and FAM72B, we also observed a statistically-
significant reduction in disease-free survival of patients
with tumours exhibiting alterations in gene expression
(p = 0.015) (Figure 3D). Our observations suggest that
these 7 genes in combination could form a panel of
biomarkers associated with early relapse from treatment
in clinical PCa.
Discussion
To the best of our knowledge, our study is the first “real
time” in vivo RNA-Seq-based transcriptome analysis ofclinical PCa from pre- and post-treatment TRUSS-guided
biopsies of patients treated with docetaxel chemotherapy
plus ADT. The limitations of our study include a targeted
TRUSS-guided needle-core biopsy strategy that may result
in heterogeneous tissue sampling with variable cellularity
and small sample numbers due to the high quality RNA
required for RNA-Seq (RIN > 6 and total RNA > 500 ng).
Despite using fresh-frozen tissue samples, the high
sample attrition rate (33%) from analyses prevented
more meaningful clinical outcomes, such as treatment
response, to be extrapolated from our results. Nonetheless,
we clearly demonstrate the feasibility of this in vivo
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from small tissue samples pre- and post-treatment
with cytotoxic chemotherapy. As tissue sample pro-
cessing and RNA-Seq methodologies are further re-
fined, it may become possible to obtain reliable sequencing
information from low input and/or degraded clinical
samples [33].
The transcriptomic landscape of PCa includes gene
fusion products as a result genomic rearrangements [31].
We observed transcripts derived from the commonly-
reported TMPRSS2/ERG gene fusion as well as other
inter- and intra-chromosomal gene fusions. Incorporating
different samples from our previously-published RNA-Seq
dataset from the same study cohort [20], we observed
transcripts arising from the TMPRSS2/ERG fusion in 28%
of all pre-treatment samples. These observations are
comparable to the frequency of TMPRSS2/ERG fusions
reported in Caucasian populations [34] as well as in an
Asian cohort analysed by RNA-Seq [35].
Our analysis of docetaxel plus ADT-driven gene
expression changes identified two differentially-regulated
genes ADAM7 and FAM72B, which were also mis-
regulated in a large proportion of prostate tumours from
a large cohort of different patients and associated with
shorter disease-free survival after treatment. Additionally,
we identified enrichment for cell cycle-related genes,
including the down-regulation of expression of some
positive regulators of cell cycle progression ~4 weeks
after the final cycle of docetaxel chemotherapy. Our
observations were somewhat reassuring, as docetaxel
in combination with ADT in vivo appears to exhibit an
expected mechanism of action on cell cycle progression.
Furthermore, we demonstrated that androgen withdrawal
did not affect the dose-dependent induction of G2/M by
docetaxel in vitro. Taken together, our data suggest a
persistent anti-tumourigenic effect of docetaxel in
combination with ADT in vivo. However the longevity
of this response may be limited, as a previous study
of docetaxel-treated tumours identified persistent PCa
several months after treatment [36].
Finally, we identify a biomarker panel of 7 genes
(ADAM7, FAM72B, BUB1B, CCNB1, CCNB2, TTK and
CDK1), which included a cell cycle-related geneset, that
was not only mis-regulated in a significant proportion of
treatment-naïve PCa specimens, but also associated with
early relapse after treatment. Recently, there has been
considerable interest in the use of cell cycle-related
genes as biomarkers of disease progression to aid treatment
decisions. The cell cycle progression (CCP) test (Prolaris®,
Myriad Genetics) is a prognostic assay based on a 46-gene
expression signature that includes cell cycle-related genes,
which, in combination with standard clinicopathological
parameters, accurately stratifies patients with primary
PCa to the risk of PCa-specific disease progression anddisease-specific mortality [37]. Based on our preliminary
findings, it is also possible that the CCP test may be useful
to determine the risk of disease relapse after cytotoxic
chemotherapy for advanced PCa.
Our study exemplifies the feasibility of in vivo RNA-
Seq-based tumour molecular profiling from pre- and
post-treatment biopsies from chemotherapy-treated
patients [8] for advanced PCa to highlight the mechanisms
of drug action and identify putative biomarkers of chemo-
sensitivity or –resistance to (such as ORM1) and/or
prognosis (such as ADAM7 and FAM72B, and the cell
cycle-related genes). Our preliminary findings suggest
that a 7 gene signature biomarker panel, which includes
cell-cycle related genes, may have prognostic value in
treatment-naïve clinical PCa and warrants further
investigation. Further similar larger-scale studies with
high-quality outcomes data will be required to allow
development of a complete oncogenomic personalised
approach to patient care for advanced/metastatic PCa,
with prognostication and treatment scheduling based
on oncogenomic profiles to maximise chemotherapy
efficacy [38].
Conclusions
Here we report on the first “real-time” in vivo RNA-Seq-
based transcriptome analysis of clinical PCa from pre- and
post-treatment TRUSS-guided biopsies of patients treated
with docetaxel chemotherapy plus ADT. We have identi-
fied a chemotherapy-driven PCa transcriptome profile
which includes the down-regulation of important positive
regulators of cell cycle progression. A 7-gene signature
biomarker panel has been identified in high-risk pros-
tate cancer patients to be of prognostic value. Future
prospective study is warranted to evaluate the clinical
value of this panel.
Additional files
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